Lung Cancer Progress and Promise: Shaping the Future of Care

M. Patricia Rivera; Catherine R. Sears

doi:10.1055/a-2703-4793

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med
DOI: 10.1055/a-2703-4793

Preface

Lung Cancer Progress and Promise: Shaping the Future of Care

Autor*innen

M. Patricia Rivera

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Rochester Medical Center, Rochester, New York
Catherine R. Sears

²Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

³Division of Pulmonology/Pulmonary Oncology, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana

Abstract

Volltext

Referenzen

References
1 Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172 (05) 523-529
2 Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin 2025; 75 (01) 10-45
3 Vachani A, Sequist LV, Spira A. AJRCCM: 100-year anniversary. The shifting landscape for lung cancer: Past, present, and future. Am J Respir Crit Care Med 2017; 195 (09) 1150-1160
4 Moolgavkar SH, Holford TR, Levy DT. et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012; 104 (07) 541-548
5 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
6 de Koning HJ, van der Aalst CM, de Jong PA. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382 (06) 503-513
7 Moghaddam SJ, Savai R, Salehi-Rad R. et al. Premalignant progression in the lung: Knowledge gaps and novel opportunities for interception of non-small cell lung cancer. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2024; 210 (05) 548-571
8 Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022; 40 (06) 611-625
9 Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol 2021; 16 (07) 1086-1098
10 Daly ME, Singh N, Ismaila N. et al. Management of stage III non-small-cell lung cancer: ASCO Guideline. J Clin Oncol 2022; 40 (12) 1356-1384
11 Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023; 20 (09) 624-639
12 Kim SY, Silvestri GA, Kim YW. et al. Screening for lung cancer, overdiagnosis, and healthcare utilization: A nationwide population-based study. J Thorac Oncol 2025; 20 (05) 577-588
13 Lim KP, Marshall H, Tammemägi M. et al; ILST (International Lung Screening Trial) Investigator Consortium. Protocol and rationale for the International Lung Screening Trial. Ann Am Thorac Soc 2020; 17 (04) 503-512
14 Rivera MP, Katki HA, Tanner NT. et al. Addressing disparities in lung cancer screening eligibility and healthcare access. An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2020; 202 (07) e95-e112
15 Rendle KA, Saia CA, Vachani A. et al. Rates of downstream procedures and complications associated with lung cancer screening in routine clinical practice: A retrospective cohort study. Ann Intern Med 2024; 177 (01) 18-28
16 Bade B, Faiz SA, Tan M, Baugh AD, Lavercombe M, Sheshadri A. The impact of health care disparities on lung cancer screening and treatment. Chest 2025; (e-pub ahead of print)
17 Young CD, Katki HA, Cheung LC. et al. Individual- and group-level disparities between racial and ethnic groups in lung cancer screening eligibility criteria. JAMA Netw Open 2025; 8 (03) e252172
18 Madrigal JM, Fisher JA, Pruitt CN. et al. Carcinogenic industrial air emissions and lung cancer risk in a cohort of 440,000 Americans. Am J Respir Crit Care Med 2025; 211 (07) 1241-1252
19 Zhu M, Han Y, Mou Y. et al. Effect of long-term fine particulate matter exposure on lung cancer incidence and mortality in Chinese nonsmokers. Am J Respir Crit Care Med 2025; 211 (04) 600-609
20 Kava CM, Siegel DA, Qin J, Sabatino SA, Wilson R, Wu M. Patterns and differences in lung cancer treatment: United States, 2015-2020. Chest 2025; 167 (04) 1218-1231